APRIL 16, 2026 AT 10:45 AM
ACHIEVE-4, the longest Phase 3 study of Eli Lilly's (LLY) Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Importance
Level 1
- FDA submission planned by end-Q2.